BofA update shows where active managers are putting money
INVO Fertility, Inc. (NASDAQ:IVF) reported Monday that an institutional investor exercised its Additional Investment Right to acquire 200 shares of the company’s Series C-2 Convertible Preferred Stock for $200,000 in cash. The transaction took place on July 28, 2025, according to a statement in a Securities and Exchange Commission filing.
The Series C-2 Preferred shares were issued at an aggregate stated value of $200,000. As a result of this exercise, the conversion price for the Series C-2 Preferred was adjusted to $1.8909 per share. The company stated that the preferred shares and any common stock issuable upon conversion were sold and issued without registration under the Securities Act, relying on exemptions for private offerings under Section 4(a)(2) and Rule 506. With a current ratio of 0.08 and EBITDA of -$8.2 million in the last twelve months, InvestingPro data reveals significant liquidity challenges for the company.
The investor involved was described as an existing holder of Series C-2 Convertible Preferred Stock. The rights to purchase the shares were provided under a Securities Purchase Agreement dated January 3, 2024, which INVO Fertility joined through a joinder agreement on October 11, 2024.
INVO Fertility’s common stock is listed on The Nasdaq Stock Market under the ticker IVF. The company is headquartered in Sarasota, Florida.
This information is based on a press release statement included in the company’s recent SEC filing.
In other recent news, INVO Fertility, Inc. announced it will implement a 1-for-3 reverse stock split effective July 21, 2025. The company also adjourned its 2025 annual meeting of stockholders, which will now reconvene on July 23, 2025, in a virtual format. Additionally, INVO Fertility has amended its Series C-2 Convertible Preferred Stock agreements, allowing holders to acquire more shares through cash purchase or by exchanging existing debentures. During the recent annual meeting, stockholders approved several key proposals, including the election of all five board of director nominees. The company also received a notice of allowance for a new patent on a modified version of its INVOcell device, extending intellectual property protection through 2040. This patent modification was based on feedback from embryologists to simplify the device design. These developments mark significant changes in INVO Fertility’s capital structure and intellectual property portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.